Investments, Funding & Disinvestment

As part of AAIB’s corporate social responsibility efforts, the system draws on cutting-edge global oncology technology.

The new facility will generate approximately 500 permanent biomanufacturing positions once operational.

Scinai will retain the plant’s entire workforce as it integrates the facility into its CDMO operations.

AbbVie plans to hire 300 new employees for the facilities, targeting engineers, scientists, manufacturing operators, and lab technicians in the North Chicago area.

Under the renewed agreement, Bora will provide end-to-end manufacturing services for more than 20 commercial GSK product lines.

The procedures took place at Al-Nasr Specialised Hospital in Port Said, representing a major advancement in accessible cardiac care for Egyptian citizens.

Novartis will continue operating its subsidiary Novartis Healthcare Private Limited, which serves as the commercial arm for the company’s operations in India.

The acquisition centers on anitocabtagene autoleucel, known as anito-cel, an investigational CAR-T cell therapy targeting multiple myeloma.

The pharmaceutical giant will pay Frontier USD 40 million upfront, with additional payments of up to USD 963 million tied to achieving specific development, regulatory, and commercial milestones.

These investments aim to elevate the standard of care available to patients while positioning Alameda as a provider of choice for complex medical procedures.